what are glp-1 medications New Guidelines for Type 2 Diabetes in 2025 How Three Types of GLP-1
Description
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition
Additionally, at 48 weeks, the same percentages were 8.7% in the 1 mg group, 24.2% in the 12 mg group, and 2.1% in the placebo group
doi: 10.1080/02699052.2019.1587000 [DOI] [PubMed] [Google Scholar] 21
For clarity, only the losses obtained for the highest dose of tirzepatide (15 mg) are shown in the figure
It means its an individualized clinical decision that falls outside what published trial data can definitively confirm
